1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Cardiovascular Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

Cardiovascular Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

  • January 2021
  • 127 pages
  • ID: 6009482
  • Format: PDF
  • Mordor Intelligence LLP
Up to $750 off Until Jul 31st 2021

Summary

Table of Contents

Search Inside

The Cardiovascular drug market studied was anticipated to grow with a CAGR of nearly 3.8% during the forecast period. The major factors driving the growth of the market are the rising global prevalence of various coronary heart diseases such as stroke, cardiomyopathy causing a global burden of cardiac deaths and favorable reimbursement initiatives. For instance, according to the Global Health And Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition in the United States which directly resulted in a higher demand for highly efficient and immediate treatment. Also, the ongoing research activities by key players to develop technologically advanced cardiovascular drugs with reduced side effects such as biosimilars, monoclonal antibodies and peptide therapies to save the life of the patients are expected to further boost the growth of the global cardiovascular drugs market revenue throughout the forecast period.

Key Market Trends
The Anti-coagulants in the Drug Class Segment are Expected to Hold the Largest Market Share in the Cardiovascular Drugs Market

Anticoagulant drugs are expected to witness the largest market share in the cardiovascular drugs market during the forecast period. This dominance is due to the increased use of these drugs in various cardiac indications owing to their ability to reduce the risk of stroke and blood clots in people with atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). Furthermore, the increased prescriptions by the physicians and patient acceptance due to their proven efficiency in managing coronary artery disease (CAD) and peripheral artery disease (PAD) which are the major cause of cardiac strokes and death contributing a significant market revenue. On the other hand, anti-arrhythmic drugs are expected to lose the market due to rise in the adoption of medical devices such as defibrillators and cardiac resynchronization therapy (CRT) pacemakers in recent years due to their automated acute hemodynamic response based on real-time changes in a patient’s cardiac condition. In contrast, anti-hypertensives are anticipated to witness the fastest growth in the forecast period due to rising awareness among the patients and their rapid use in prevention of severe complications such as stroke and myocardial infarction propelling the market growth across the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall cardiovascular drug market throughout the forecast period. The major factors attributing to the growth are deskbound lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases such as diabetes & obesity leading to rising in the prevalence of multiple cardiovascular diseases like CAD, strokes and atrial fibrillation in the United States necessitated the efficient CVD treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases among which CAD was the major cause of death resulted in higher demand for better treatment with efficient medication driving the market in the United States contributing to the outstanding share of revenue propelling the global cardiovascular drugs market throughout the forecasted period.

Competitive Landscape
The cardiovascular drugs market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in May 2019, Pfizer Inc received approval from the U.S. Food and Drug Administration (FDA) for its two oral formulations VYNDAQEL and VYNDAMAX, the first and only medicines indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization which is further expected to foster the global cardiovascular drugs market growth throughout the forecast period. Some of the companies which are currently dominating the market are C. H. Boehringer Sohn AG & Co KG, Amgen Inc, Baxter International Inc, Pfizer Inc, and Novartis AG.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

$4250

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Middle East and Africa Cardiac Rehabilitation Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Application, and End User

  • $ 3000
  • June 2021
  • 132 pages

The Middle East and Africa cardiac rehabilitation market is expected to reach US$ 90.26 million by 2028 from US$ 59.97 million in 2020; it is estimated to grow at a CAGR of 5.3% from 2021 to 2028. The ...

  • Middle East
  • Africa
  • Healthcare
  • Cardiovascular Disease
  • Industry analysis
  • Cause-Specific Mortality Rate
  • Smoking Prevalence

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on